A Phase 1/2 interventional study of INCB057643 and Gemcitabine in Solid Tumors, sponsored by Incyte Corporation. Terminated at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.
Sponsored by Incyte Corporation · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Lymphoma by Incyte Corporation — 1 open to participants now, 1 under way, none of them phase 3. Lymphoma · Incyte Corporation.
Among the 15 studies in Lymphoma by Incyte Corporation, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 1/2, and was the 5th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 15 studies in Lymphoma by Incyte Corporation is open now, in 7 countries. Recruiting first, the newest first:
Incyte Biosciences International Sàrl · Sites in Belgium, France, Italy and 4 more countries
Ages 1–17
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12
First in 2014; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 84 across the 14 interventional studies, 102 across the 1 observational. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Lymphoma by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies.
Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 in select tumor types including solid tumors, lymphomas and other hematologic malignancies. Part 3 will determine the tolerated dose of INCB057643 in combination with select SOC agents; and assess the safety and tolerability of the combination therapy in select advanced solid tumors and hematologic malignancies. Part 4 will further evaluate the safety, preliminary efficacy, PK, and PD of the selected dose combination from Part 3 in 4 specific advanced solid tumor and hematologic malignancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed diagnosis of advanced or :
(ECOG) performance status
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA. Treatment Group A included solid tumors and lymphoma
Drug: INCB057643
Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA. Treatment Group A included solid tumors and lymphoma
Drug: INCB057643
Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA. Treatment Group A included solid tumors and lymphoma
Drug: INCB057643
Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF
Drug: INCB057643
Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF.
Drug: INCB057643
Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group C (TGC), based on protocol-specific criteria. Treatment Group C includes subjects with MM
Drug: INCB057643
Initial cohort dose of INCB054763 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group A (TGA), based on protocol-specific criteria. Part 2 Treatment Group A expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.
Drug: INCB057643
Initial cohort dose of INCB057463 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group B (TGB), based on protocol-specific criteria. Part 2 Treatment Group B expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.
Drug: INCB057643
Initial cohort dose of INCB057643 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Gemcitabine) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies where Gemcitabine is relevant
Drug: INCB057643 · Drug: Gemcitabine
Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Paclitaxel) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.
Drug: INCB057643 · Drug: Paclitaxel
Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Rucaparib) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.
Drug: INCB057643 · Drug: Rucaparib
Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Abiraterone + Prednisone) in Castration Resistant Prostrate Cancer
Drug: INCB057643 · Drug: Abiraterone
Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Ruxolitinib) in Myelofibrosis.
Drug: INCB057643 · Drug: Ruxolitinib
Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Azacitidine) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Drug: INCB057643 · Drug: Azacitidine
Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
Standard of Care (SOC) agents
Standard of Care (SOC) agents
Standard of Care (SOC) agents
Standard of Care (SOC) agents
Standard of Care (SOC) agents
Standard of Care (SOC) agents
Number of Participants With Treatment Emergent Adverse Events (TEAE's).
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
Time frame: From screening through at least 30 days after end of treatment, up to approximately 24 months
Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay
An ex vivo assay (utilized in monotherapy only), Measuring Total c-Myc protein expressed from an exogenously added cell line (KMS12BM) to patient plasma, before and after administration of INCB057643.
Time frame: PD in plasma at pre-dose and 0.5, 1, 2, 4, 6 and 8 hours postdose, for C1D1 and C1D8, and 24hrs post dose for C1D1
Objective Response Rate (ORR) With INCB057643 in Solid Tumors
Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response \[complete response (CR) or partial response (PR)\].
Time frame: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months
Cmax: Maximum Observed Plasma Concentration of INCB057643.
Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fasted state.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8
Tmax: Time to Maximum Plasma Concentration of INCB057643
Time to maximum plasma concentration of INCB057643 administered as monotherapy in fasted state
Time frame: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8
AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643
Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration of INCB057643 administered as monotherapy in fasted state
Time frame: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy
Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fasted state
Time frame: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D8
Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.
Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fed state.
Time frame: C2D1
Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643
Time to maximum plasma concentration of INCB057643 administered as monotherapy in fed state
Time frame: C2D1
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy
Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fed state.
Time frame: C2D1
A total of 137 subjects enrolled at 19 different sites in USA.
| Milestone | Part1/Treatment Group A : 8mg QD INCB057643 | Part1/Treatment Group A : 12mg QD INCB057643 | Part1/Treatment Group A : 16mg QD INCB057643 | Part1/Treatment Group B : 8mg QD INCB057643 | Part1/Treatment Group B : 12mg QD INCB057643 | Part1/Treatment Group C : 8mg QD INCB057643 | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg | Enrolled But Not Dosed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 5 | 8 | 7 | 5 | 1 | 86 | 5 | 1 | 2 | 4 | 3 | 1 | 2 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 5 | 8 | 7 | 5 | 1 | 86 | 5 | 1 | 2 | 4 | 3 | 1 | 2 | 3 |
| Withdrew: Death | 1 | 4 | 5 | 5 | 3 | 1 | 61 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 2 | 1 | 1 | 0 | 12 | 2 | 1 | 1 | 3 | 2 | 1 | 1 | 2 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
| Participants | Part1/Treatment Group A : 8mg QD INCB057643 | Part1/Treatment Group A : 12mg QD INCB057643 | Part1/Treatment Group A : 16mg QD INCB057643 | Part1/Treatment Group B : 8mg QD INCB057643 | Part1/Treatment Group B : 12mg QD INCB057643 | Part1/Treatment Group C : 8mg QD INCB057643 | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAE's). | 4 | 5 | 8 | 7 | 5 | 1 | 86 | 5 | 1 | 2 | 4 | 3 | 1 | 2 |
An ex vivo assay (utilized in monotherapy only), Measuring Total c-Myc protein expressed from an exogenously added cell line (KMS12BM) to patient plasma, before and after administration of INCB057643.
| %Inhibition of Total c-Myc | 8mg QD INCB057643 | 12mg QD INCB057643 | 16mg QD INCB057643 |
|---|---|---|---|
| C1D1 | 24 ± 199.5 | 28 ± 200.1 | 54 ± 236.3 |
| C1D8 | 30 ± 42.59 | 43.4 ± 52.7 | 65 ± 55.21 |
Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response \[complete response (CR) or partial response (PR)\].
| Participants | Part1/Treatment Group A : 8mg QD INCB057643 | Part1/Treatment Group A : 12mg QD INCB057643 | Part1/Treatment Group A : 16mg QD INCB057643 | Part1/Treatment Group B : 8mg QD INCB057643 | Part1/Treatment Group B : 12mg QD INCB057643 | Part1/Treatment Group C : 8mg QD INCB057643 | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solid Tumors | 0 | 0 | 0 | — | — | — | 0 | — | 0 | 1 | 0 | 0 | — | — |
| Lymphoma | 1 | 0 | 1 | — | — | — | 2 | — | — | — | — | — | — | — |
| AML | — | — | — | 0 | 0 | — | — | 1 | — | — | — | — | — | 0 |
| Glioblastoma | — | — | — | — | — | — | 0 | — | — | — | — | — | — | — |
| Myelodysplastic Syndrome | — | — | — | 0 | 0 | — | — | 0 | — | — | — | — | — | — |
| Myelofibrosis | — | — | — | 0 | — | — | — | 0 | — | — | — | — | 0 | — |
| Multiple Myeloma | — | — | — | — | — | 0 | — | — | — | — | — | — | — | — |
Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fasted state.
| nM | 8mg QD INCB057643 | 12mg QD INCB057643 | 16mg QD INCB057643 |
|---|---|---|---|
| C1D1 | 201 ± 83.6 | 266 ± 94.7 | 343 ± 93.2 |
| C1D8 | 210 ± 93.2 | 293 ± 113 | 340 ± 165 |
Time to maximum plasma concentration of INCB057643 administered as monotherapy in fasted state
| hours | 8mg QD INCB057643 | 12mg QD INCB057643 | 16mg QD INCB057643 |
|---|---|---|---|
| C1D1 | 2.00 (1.00 to 24.00) | 2 (0.50 to 8.00) | 2.00 (2.00 to 4.00) |
| C1D8 | 1.00 (1.00 to 4.00) | 2 (0.50 to 8.00) | 2.00 (2.00 to 4.00) |
Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration of INCB057643 administered as monotherapy in fasted state
| h*nM | 8mg QD INCB057643 | 12mg QD INCB057643 | 16mg QD INCB057643 |
|---|---|---|---|
| AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643 | 2090 ± 50.1 | 2550 ± 39.5 | 3210 ± 34.3 |
Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fasted state
| h*nM | 8mg QD INCB057643 | 12mg QD INCB057643 | 16mg QD INCB057643 |
|---|---|---|---|
| AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy | 1940 ± 45.1 | 2740 ± 43.2 | 3610 ± 71.9 |
Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fed state.
| nM | 12mg QD INCB057643 |
|---|---|
| Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643. | 220 ± 32.0 |
Time to maximum plasma concentration of INCB057643 administered as monotherapy in fed state
| hours | 12mg QD INCB057643 |
|---|---|
| Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643 | 6.00 (4.00 to 8.00) |
Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fed state.
| h*nM | 12mg QD INCB057643 |
|---|---|
| AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy | 2980 ± 31.5 |
Collected over From screening through at least 30 days after end of treatment, up to approximately 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part1/Treatment Group A : 8mg QD INCB057643 | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Part1/Treatment Group A : 12mg QD INCB057643 | 4/5 (80%) | 1/5 (20%) | 5/5 (100%) |
| Part1/Treatment Group A : 16mg QD INCB057643 | 5/8 (62.5%) | 4/8 (50%) | 7/8 (87.5%) |
| Part1/Treatment Group B : 8mg QD INCB057643 | 6/7 (85.7%) | 5/7 (71.4%) | 7/7 (100%) |
| Part1/Treatment Group B : 12mg QD INCB057643 | 4/5 (80%) | 4/5 (80%) | 5/5 (100%) |
| Part1/Treatment Group C : 8mg QD INCB057643 | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) |
| Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | 68/86 (79.1%) | 32/86 (37.2%) | 82/86 (95.3%) |
| Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | 3/5 (60%) | 4/5 (80%) | 5/5 (100%) |
| Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | 1/2 (50%) | 0/2 (0%) | 2/2 (100%) |
| Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | 1/4 (25%) | 0/4 (0%) | 4/4 (100%) |
| Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Part1/Treatment Group A : 8mg QD INCB057643 | Part1/Treatment Group A : 12mg QD INCB057643 | Part1/Treatment Group A : 16mg QD INCB057643 | Part1/Treatment Group B : 8mg QD INCB057643 | Part1/Treatment Group B : 12mg QD INCB057643 | Part1/Treatment Group C : 8mg QD INCB057643 | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Herpes zosterInfections and infestations | 0/4 | 0/5 | 0/8 | 0/7 | 0/5 | 0/1 | 0/86 | 0/5 | 0/1 | 0/2 | 0/4 | 0/3 | 1/1 | 0/2 |
| Septic shockInfections and infestations | 0/4 | 0/5 | 0/8 | 0/7 | 0/5 | 1/1 | 0/86 | 0/5 | 0/1 | 0/2 | 0/4 | 0/3 | 0/1 | 0/2 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 0/5 | 0/8 | 1/7 | 2/5 | 0/1 | 0/86 | 2/5 | 0/1 | 0/2 | 0/4 | 0/3 | 0/1 | 0/2 |
| Acute kidney injuryRenal and urinary disorders | 0/4 | 0/5 | 0/8 | 2/7 | 0/5 | 0/1 | 1/86 | 0/5 | 0/1 | 0/2 | 0/4 | 1/3 | 0/1 | 0/2 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/5 | 0/8 | 0/7 | 0/5 | 0/1 | 2/86 | 0/5 | 0/1 | 0/2 | 0/4 | 1/3 | 0/1 | 0/2 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/4 | 0/5 | 1/8 | 0/7 | 0/5 | 0/1 | 0/86 | 0/5 | 0/1 | 0/2 | 0/4 | 1/3 | 0/1 | 0/2 |
| TachycardiaCardiac disorders | 0/4 | 0/5 | 0/8 | 0/7 | 0/5 | 0/1 | 0/86 | 0/5 | 0/1 | 0/2 | 0/4 | 1/3 | 0/1 | 0/2 |
| PneumoniaInfections and infestations | 0/4 | 0/5 | 1/8 | 2/7 | 0/5 | 0/1 | 1/86 | 1/5 | 0/1 | 0/2 | 0/4 | 0/3 | 0/1 | 0/2 |
| Performance status decreasedGeneral disorders | 1/4 | 0/5 | 0/8 | 0/7 | 0/5 | 0/1 | 0/86 | 0/5 | 0/1 | 0/2 | 0/4 | 0/3 | 0/1 | 0/2 |
| SepsisInfections and infestations | 1/4 | 0/5 | 0/8 | 1/7 | 0/5 | 0/1 | 4/86 | 1/5 | 0/1 | 0/2 | 0/4 | 0/3 | 0/1 | 0/2 |
| Event | Part1/Treatment Group A : 8mg QD INCB057643 | Part1/Treatment Group A : 12mg QD INCB057643 | Part1/Treatment Group A : 16mg QD INCB057643 | Part1/Treatment Group B : 8mg QD INCB057643 | Part1/Treatment Group B : 12mg QD INCB057643 | Part1/Treatment Group C : 8mg QD INCB057643 | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/4 | 1/5 | 3/8 | 4/7 | 3/5 | 0/1 | 15/86 | 4/5 | 0/1 | 1/2 | 2/4 | 0/3 | 1/1 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 2/5 | 3/8 | 4/7 | 1/5 | 0/1 | 21/86 | 1/5 | 0/1 | 0/2 | 2/4 | 0/3 | 1/1 | 1/2 |
| DizzinessNervous system disorders | 1/4 | 1/5 | 1/8 | 0/7 | 0/5 | 0/1 | 10/86 | 1/5 | 0/1 | 0/2 | 0/4 | 0/3 | 1/1 | 0/2 |
| FallInjury, poisoning and procedural complications | 0/4 | 0/5 | 1/8 | 2/7 | 1/5 | 0/1 | 4/86 | 0/5 | 0/1 | 0/2 | 0/4 | 0/3 | 1/1 | 0/2 |
| Herpes zosterInfections and infestations | 1/4 | 0/5 | 1/8 | 0/7 | 0/5 | 0/1 | 5/86 | 0/5 | 0/1 | 0/2 | 0/4 | 0/3 | 1/1 | 0/2 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/4 | 0/5 | 3/8 | 1/7 | 0/5 | 0/1 | 13/86 | 0/5 | 0/1 | 0/2 | 0/4 | 1/3 | 1/1 | 0/2 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/4 | 0/5 | 0/8 | 0/7 | 0/5 | 0/1 | 2/86 | 0/5 | 0/1 | 0/2 | 0/4 | 0/3 | 1/1 | 0/2 |
| Oedema peripheralGeneral disorders | 0/4 | 0/5 | 0/8 | 0/7 | 0/5 | 0/1 | 2/86 | 1/5 | 0/1 | 0/2 | 0/4 | 1/3 | 1/1 | 0/2 |
| Platelet count decreasedInvestigations | 1/4 | 0/5 | 0/8 | 1/7 | 2/5 | 0/1 | 8/86 | 0/5 | 0/1 | 0/2 | 1/4 | 0/3 | 1/1 | 0/2 |
| Post herpetic neuralgiaNervous system disorders | 0/4 | 0/5 | 0/8 | 0/7 | 0/5 | 0/1 | 0/86 | 0/5 | 0/1 | 0/2 | 0/4 | 0/3 | 1/1 | 0/2 |
| Age, Continuous(Years) | Part1/Treatment Group A : 8mg QD INCB057643 | Part1/Treatment Group A : 12mg QD INCB057643 | Part1/Treatment Group A : 16mg QD INCB057643 | Part1/Treatment Group B : 8mg QD INCB057643 | Part1/Treatment Group B : 12mg QD INCB057643 | Part1/Treatment Group C : 8mg QD INCB057643 | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg | Enrolled But Not Dosed | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.3 ± 10.21 | 60.2 ± 12.26 | 60.5 ± 11.44 | 68.9 ± 5.81 | 75.8 ± 7.33 | 70.0 ± NA | 60.6 ± 13.80 | 72.6 ± 10.92 | 72.0 ± 0 | 56.0 ± 12.73 | 66.0 ± 6.16 | 67.7 ± 4.04 | 75.0 ± 0 | 76.5 ± 2.12 | 66.0 ± 6.24 | 63.0 ± 12.80 |
| Sex: Female, Male(Participants) | Part1/Treatment Group A : 8mg QD INCB057643 | Part1/Treatment Group A : 12mg QD INCB057643 | Part1/Treatment Group A : 16mg QD INCB057643 | Part1/Treatment Group B : 8mg QD INCB057643 | Part1/Treatment Group B : 12mg QD INCB057643 | Part1/Treatment Group C : 8mg QD INCB057643 | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg | Enrolled But Not Dosed | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 5 | 3 | 1 | 0 | 48 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 1 | 68 |
| Male | 2 | 3 | 3 | 4 | 4 | 1 | 38 | 5 | 0 | 1 | 0 | 3 | 1 | 2 | 2 | 69 |
| Race/Ethnicity, Customized(Participants) | Part1/Treatment Group A : 8mg QD INCB057643 | Part1/Treatment Group A : 12mg QD INCB057643 | Part1/Treatment Group A : 16mg QD INCB057643 | Part1/Treatment Group B : 8mg QD INCB057643 | Part1/Treatment Group B : 12mg QD INCB057643 | Part1/Treatment Group C : 8mg QD INCB057643 | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg | Enrolled But Not Dosed | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White/Caucasian | 3 | 3 | 5 | 6 | 4 | 0 | 71 | 5 | 0 | 1 | 4 | 3 | 1 | 2 | 3 | 111 |
| Black/African American | 1 | 0 | 2 | 1 | 0 | 0 | 10 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 16 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian/Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2016 to primary completion in Feb 2019, 32 months.
Results were first posted in Apr 2022, 3 years 2 months after primary completion. A results delay was requested in Feb 2020.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: INCB057643